Zoetis Q3 Net Income Jumps 5.7% on Modest Revenue Growth

TL;DR

**Zoetis is a buy; strong net income growth and strategic focus outweigh debt increase.**

AI Summary

Zoetis Inc. reported a modest revenue increase of 0.5% to $2.400 billion for the three months ended September 30, 2025, up from $2.388 billion in the prior year. Net income attributable to Zoetis Inc. stockholders rose by 5.7% to $721 million, compared to $682 million in the same quarter of 2024. For the nine months ended September 30, 2025, revenue increased by 2.0% to $7.080 billion from $6.939 billion, and net income grew by 8.7% to $2.070 billion from $1.905 billion. Diluted earnings per share for the nine-month period increased to $4.65 from $4.18. The company's total assets expanded to $15.159 billion as of September 30, 2025, from $14.237 billion at December 31, 2024, driven by increases in cash and cash equivalents, accounts receivable, and inventories. Long-term debt, net of discount and issuance costs, significantly increased to $7.069 billion from $5.220 billion, reflecting new senior notes issuance of $1.848 billion. Zoetis completed the divestiture of its medicated feed additive product portfolio on October 31, 2024, streamlining its major product categories.

Why It Matters

Zoetis's consistent growth in net income and EPS, despite a modest revenue increase, signals strong operational efficiency and profitability, which is crucial for investors seeking stable returns in the animal health sector. The significant increase in long-term debt to $7.069 billion, up from $5.220 billion, could impact future financial flexibility and interest coverage, a key concern for debt-conscious investors. For employees and customers, the divestiture of the medicated feed additive portfolio on October 31, 2024, indicates a strategic focus on core product categories like parasiticides and vaccines, potentially leading to more specialized offerings and R&D investments. In a competitive market, this strategic streamlining could enhance Zoetis's position against rivals by concentrating resources on high-growth areas.

Risk Assessment

Risk Level: medium — The company's long-term debt increased significantly to $7.069 billion as of September 30, 2025, from $5.220 billion at December 31, 2024, representing a 35.4% increase. This substantial rise in debt, primarily from $1.848 billion in senior notes, could expose Zoetis to higher interest rate risks and reduce financial flexibility, despite healthy net income growth of $721 million for the quarter.

Analyst Insight

Investors should consider Zoetis Inc. (ZTS) for its consistent net income growth and strategic focus on core animal health products. While the increase in long-term debt warrants monitoring, the company's strong cash flow from operations of $2.011 billion for the nine months ended September 30, 2025, suggests it can manage its obligations. Maintain a 'hold' position and watch for further details on debt management and R&D pipeline.

Financial Highlights

debt To Equity

0.79

revenue

$7.080B

operating Margin

30.0%

total Assets

$15.159B

total Debt

$7.069B

net Income

$2.070B

eps

$4.65

gross Margin

71.5%

cash Position

$1.759B

revenue Growth

+2.0%

Revenue Breakdown

Key Numbers

• $2.400B — Revenue (Increased 0.5% for Q3 2025 compared to Q3 2024)
• $721M — Net Income (Increased 5.7% for Q3 2025 compared to Q3 2024)
• $7.080B — Revenue (Increased 2.0% for nine months ended September 30, 2025)
• $2.070B — Net Income (Increased 8.7% for nine months ended September 30, 2025)
• $4.65 — Diluted EPS (Increased from $4.18 for nine months ended September 30, 2025)
• $7.069B — Long-term Debt (Increased 35.4% from December 31, 2024)
• $1.848B — Proceeds from Debt Issuance (New senior notes issued during nine months ended September 30, 2025)
• 440.7M — Common Shares Outstanding (As of October 31, 2025)
• $2.011B — Net Cash Provided by Operating Activities (For nine months ended September 30, 2025)
• $1.000 — Dividends Declared per Common Share (For nine months ended September 30, 2025)

Key Players & Entities

• Zoetis Inc. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• $2.400 billion (dollar_amount) — revenue for three months ended September 30, 2025
• $721 million (dollar_amount) — net income attributable to Zoetis Inc. for three months ended September 30, 2025
• $7.069 billion (dollar_amount) — long-term debt as of September 30, 2025
• $1.848 billion (dollar_amount) — proceeds from issuance of long-term debt
• $4.65 (dollar_amount) — diluted EPS for nine months ended September 30, 2025
• FASB (regulator) — Financial Accounting Standards Board
• New York Stock Exchange (regulator) — exchange where ZTS is registered
• October 31, 2024 (date) — divestiture of medicated feed additive product portfolio

FAQ

Risk Factors

• Product Approval and Regulatory Scrutiny [high — regulatory]: Zoetis operates in a highly regulated industry. Delays or failures in obtaining regulatory approvals for new products, or changes in regulatory requirements for existing products, could adversely affect the company's ability to market and sell its products. For example, the FDA and other global regulatory bodies continuously review product safety and efficacy.
• Competition and Pricing Pressure [medium — market]: The animal health market is competitive, with established players and emerging companies. Increased competition, including from generic products, could lead to pricing pressures and reduced market share. Zoetis faces competition from companies like Elanco, Merck Animal Health, and Boehringer Ingelheim.
• Supply Chain Disruptions [medium — operational]: Disruptions in the global supply chain, including raw material shortages, manufacturing issues, or logistics challenges, could impact Zoetis's ability to produce and deliver products to customers. The company relies on a complex global network for its manufacturing and distribution.
• Foreign Currency Exchange Rate Fluctuations [medium — financial]: As a global company, Zoetis generates a significant portion of its revenue and incurs expenses in foreign currencies. Fluctuations in exchange rates can impact reported financial results, as seen in the $240 million increase in foreign currency translation adjustments for the nine months ended September 30, 2025.
• Intellectual Property Protection [medium — legal]: The company's success depends on its ability to protect its intellectual property, including patents, trademarks, and trade secrets. Infringement of its intellectual property rights or challenges to its patent validity could negatively impact its competitive position and profitability.
• Divestiture Integration and Execution [low — operational]: While the divestiture of the medicated feed additive portfolio streamlines operations, the execution of such strategic transactions carries inherent risks, including potential disruptions to ongoing business and challenges in realizing anticipated benefits. The company completed this divestiture on October 31, 2024.

Industry Context

The animal health industry is characterized by increasing demand for pet care and a growing need for disease prevention and treatment in livestock. Key trends include the humanization of pets, advancements in veterinary medicine, and a focus on sustainable agriculture. Zoetis operates in a competitive landscape with major players like Elanco, Merck Animal Health, and Boehringer Ingelheim, all vying for market share through innovation and strategic acquisitions.

Regulatory Implications

Zoetis faces significant regulatory oversight from bodies like the FDA and EMA. Compliance with evolving regulations regarding product safety, efficacy, and manufacturing standards is critical. Any adverse regulatory actions, such as product recalls or stricter approval processes, could materially impact financial performance and market access.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Third Quarter and Nine-Month Period — Reporting period for the financial results discussed in the 10-Q, showing revenue growth and increased net income.
• 2024-10-31: Divestiture of Medicated Feed Additive Product Portfolio Completed — Streamlined product categories, impacting revenue mix and potentially future growth strategies.
• 2025-09-30: Balance Sheet Date — Reflects total assets of $15.159 billion and total debt of $7.069 billion, indicating significant asset growth and increased leverage.
• 2025-09-30: Nine Months Ended — Period during which $1.848 billion in new senior notes were issued, contributing to the increase in long-term debt.

Glossary

Noncontrolling Interests

Represents the portion of equity in a subsidiary that is not attributable to the parent company. In this filing, it was minimal or zero for net income and comprehensive income. (Helps understand the net income and comprehensive income attributable solely to Zoetis Inc. stockholders.)

Amortization of Intangible Assets

The systematic allocation of the cost of an intangible asset over its useful life. For Zoetis, this relates to acquired intellectual property and other intangible assets. (A non-cash expense that reduces reported net income, reflecting the consumption of value from acquired intangibles.)

Weighted-average common shares outstanding

The average number of common shares outstanding during a reporting period, adjusted for the timing of share issuances or repurchases. Used to calculate EPS. (Crucial for calculating Earnings Per Share (EPS), showing a decrease from 455.4 million (basic) in Q3 2024 to 442.9 million (basic) in Q3 2025.)

Comprehensive Income

Includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. It encompasses net income and other comprehensive income (OCI). (Provides a broader view of the company's financial performance, including unrealized gains/losses on derivatives and foreign currency translation adjustments.)

Senior Notes

A type of debt security that ranks higher in priority than subordinated debt in the event of bankruptcy or liquidation. Zoetis issued $1.848 billion in new senior notes. (Indicates a significant increase in the company's long-term debt obligations, impacting its capital structure and financial leverage.)

Year-Over-Year Comparison

Zoetis has demonstrated modest top-line growth, with revenue increasing by 0.5% year-over-year for the third quarter and 2.0% for the nine-month period. Net income has shown stronger growth, up 5.7% for the quarter and 8.7% for the nine months, indicating improved profitability and margin expansion. The company's balance sheet reflects significant changes, with total assets growing to $15.159 billion and long-term debt substantially increasing to $7.069 billion due to new debt issuance, signaling a shift towards higher financial leverage. Risk factors remain consistent, focusing on regulatory, market, and operational challenges, with no new major risks explicitly highlighted in this period's filing.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange

Filing Documents

• zts-20250930.htm (10-Q) — 2281KB
• rpletteragreement_102925ex.htm (EX-10.2) — 107KB
• a10qex311q32025.htm (EX-31.1) — 9KB
• a10qex312q32025.htm (EX-31.2) — 9KB
• a10qex321q32025.htm (EX-32.1) — 4KB
• a10qex322q32025.htm (EX-32.2) — 4KB
• image_0.jpg (GRAPHIC) — 36KB
• image_1.jpg (GRAPHIC) — 7KB
• 0001555280-25-000274.txt ( ) — 10519KB
• zts-20250930.xsd (EX-101.SCH) — 54KB
• zts-20250930_cal.xml (EX-101.CAL) — 79KB
• zts-20250930_def.xml (EX-101.DEF) — 305KB
• zts-20250930_lab.xml (EX-101.LAB) — 703KB
• zts-20250930_pre.xml (EX-101.PRE) — 533KB
• zts-20250930_htm.xml (XML) — 1795KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 1

Financial Statements

Item 1. Financial Statements 1 Condensed Consolidated Statements of Income (Unaudited) 1 Condensed Consolidated Statements of Comprehensive Income (Unaudited) 2 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Equity (Unaudited) 4 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 40

— OTHER INFORMATION

PART II — OTHER INFORMATION 41

Legal Proceedings

Item 1. Legal Proceedings 41

Risk Factors

Item 1A. Risk Factors 41

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43

Defaults Upon Senior Securities 43

Item 3. Defaults Upon Senior Securities 43

Mine Safety Disclosures 43

Item 4. Mine Safety Disclosures 43

Other Information 43

Item 5. Other Information 43

Exhibits

Item 6. Exhibits 44

SIGNATURES

SIGNATURES 45 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ZOETIS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Three Months Ended Nine Months Ended September 30, September 30, (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) 2025 2024 2025 2024 Revenue $ 2,400 $ 2,388 $ 7,080 $ 6,939 Costs and expenses: Cost of sales 683 701 1,954 2,012 Selling, general and administrative expenses 579 565 1,759 1,693 Research and development expenses 170 167 499 500 Amortization of intangible assets 32 35 97 107 Restructuring charges and certain acquisition and divestiture-related costs 4 5 34 51 Interest expense, net of capitalized interest 58 57 165 174 Other (income)/deductions—net ( 13 ) ( 16 ) ( 27 ) 1 Income before provision for taxes on income 887 874 2,599 2,401 Provision for taxes on income 166 182 529 486 Net income before allocation to noncontrolling interests 721 692 2,070 1,915 Less: Net income/(loss) attributable to noncontrolling interests — 10 — 10 Net income attributable to Zoetis Inc. $ 721 $ 682 $ 2,070 $ 1,905 Earnings per share attributable to Zoetis Inc. stockholders: Basic $ 1.63 $ 1.51 $ 4.65 $ 4.18 Diluted $ 1.63 $ 1.50 $ 4.65 $ 4.18 Weighted-average common shares outstanding: Basic 442.9 452.9 445.2 455.4 Diluted 443.2 453.5 445.6 456.1 Dividends declared per common share $ — $ — $ 1.000 $ 0.864 See notes to condensed consolidated financial statements. 1 | Table of Contents ZOETIS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Three Months Ended Nine Months Ended September 30, September 30, (MILLIONS OF DOLLARS) 2025 2024 2025 2024 Net income before allocation to noncontrolling interests $ 721 $ 692 $ 2,070 $ 1,915 Other comprehensive income/(loss), net of tax (a) : Unrealized losses on derivatives for cash flow hedges, net of tax of $ — and $( 1 ) for the three months ended September 30, 2025 and 2024, respectively, and $( 5 ) and $( 1 ) for the nine